Cancer Research and Treatment

Volume 33(6); December 2001

Original Articles

A Phase II Study of Genexol(R) (paclitaxel) in Metastatic Breast Cancer: Joo Young Jung, Hyun Chul Jeong, Sung Soo Yoon, Jae Hoon Lee, Jun Seok Kim, Hyo Jin Kim, Ki Hyun Kim, Jun O Park, Won Seop Lee, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; Cancer Res Treat. 2001;33(6):451-457. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.451

PURPOSE
Paclitaxel is a very effective agent in the treatment of breast cancer. Samyang Corporation has developed its own process to produce paclitaxel in a large volume using plant cell culture technology. To evaluate the efficacy and safety of Genexol(R) in patients with metastatic breast cancer who have failed to respond to standard therapy, we performed a prospective, multi- center phase II clinical trial.
MATERIALS AND METHODS
Patients with metastatic breast cancer were included in this study. Enrollees were required to have histologically confirmed breast cancer with bidimensionally measurable metastatic disease. Genexol(R) was administered at 175 mg/m2 as a 3-hour intravenous infusion every 3 weeks. All patients were premedicated with hydrocortisone, pheniramine maleate, and H2 blocker 30 minutes prior to paclitaxel. We planned to administer at least 4 courses of paclitaxel unless there was disease progression or unacceptable toxicity and to continue treatment up to a total of 6 courses in cases of objective response following 4 courses.
RESULTS
The median duration of follow-up was 8.9 (2.07~13.7) months. Forty-five patients were registered and 43 were eligible. The performance status of patients was ECOG 0~1 in 39 patients (90.7%) and 2 in 4 (9.3%). The location of metastases at the start of the study were the lung (15 patients), liver (8 patients), lymph nodes (22 patients), and other (7 patients). Among the 40 evaluable patients, 15 patients obtained partial responses (PRs) (37.5%, 95% CI: 22.5~52.5%). The median duration of response was 11.67 (4.1~11.7) months and the median time to progression was 7.73 (2.8~11.7) months. The median survival time was not reached at 13.7 months, and the overall survival rate at 13.7 months was 70.1%. The hematologic toxicity was primarily neutropenia with grade 3 or 4 in 10 patients (23.3%). The grade 3 or 4 non-hematologic toxicities included alopecia (17, 39.5%), myalgia (2, 4.7%), neuropathy (2, 4.7%), and pruritus (1, 2.3%). Mild hypersensitivity reaction was observed in 2 patients, although it did not cause withdrawal of the test drug.
CONCLUSION
The results suggest that the Genexol injection is an effective anticancer formulation for the treatment of metastatic breast cancer and toxicity is acceptable.

Citations

Citations to this article as recorded by

Current status of nanomedicine in the chemotherapy of breast cancer
A. I. Fraguas-Sánchez, C. Martín-Sabroso, A. Fernández-Carballido, A. I. Torres-Suárez
Cancer Chemotherapy and Pharmacology.2019; 84(4): 689. CrossRef
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
H. Chang, S.Y. Rha, H.-C. Jeung, C.-K. Im, J.B. Ahn, W.S. Kwon, N.C. Yoo, J.K. Roh, H.C. Chung
Annals of Oncology.2009; 20(2): 272. CrossRef

5,274 View
42 Download
2 Crossref

Clinical Analysis of Phyllodes Tumor of the Breast: Sang Hoon Han, Woon Gi Lee, Kyung Ho Cha, Tae Hoon Lee, Dong Bock Shin, Seung Yun Ha, Heung Gyu Park; Cancer Res Treat. 2001;33(6):458-462. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.458

Abstract PDF: PURPOSE
Phyllodes tumors are fibroepithelial mammary lesions that tend to behave in a benign fashion but may undergo sarcomatous transformation. They account for 0.3 to 0.5 percent of all breast tumors. Their behavior is not well understood by many clinicians.
MATERIALS AND METHODS
We retrospectively reviewed the clinical, radiologic, and pathologic finding and treatment modality of 31 patients of phyllodes tumor diagnosed at the Breast Clinic, Gachon Medical School Gil Medical Center between July 1992 and July 2000.
RESULTS
Pathologically, 6 patients (19.3%) had malignant tumor and 25 patients (80.7%) had benign lesions. All were women with average age of 36 years. The patients with malignant tumors tended to be older and had larger tumors and shorter duration. For preoperative diagnosis, we used mammography, sonography, and MIBI Scintimammography, fine needle aspiration cytology and biopsy. All these diagnostic methods suggested the diagnosis of phyllodes tumors in only 8 cases (26%). All patients received surgical treatment: excision in 21 cases, wide excision in 3 cases, simple mastectomy in 5 cases, and simple mastectomy with axillary lymph node dissection 2 cases. One patient with malignant tumor, two patients with borderline tumor and three patients with benign tumor experienced recurrence (19.3%).
CONCLUSION
None of the clinical or radiologic characteristics was useful in predicting for phyllodes tumor. Phyllodes tumors were difficult to make proper preoperative diagnoses and to differ malignant tumor from a benign one. This led to a simple excision and resulted in high local recurrence. We suggest that the initial or subsequent wide excision is an appropriate surgery to decrease the recurrence.

3,938 View
24 Download

Sarcoma and Sarcomatous Metaplastic Carcinoma of the Breast: Sang Han Yu, Woo Chul Noh, Ho Yoon Bang, Dae Yong Hwang, Dong Wook Choi, Jong Inn Lee, Nam Sun Paik, Nan Mo Moon, Jin Haeng Jung; Cancer Res Treat. 2001;33(6):463-468. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.463

Abstract PDF

PURPOSE
Primary sarcoma and SMC (sarcomatous metaplastic carcinoma) of the breast are very rare tumors, accounting for less than 1% of all breast malignancies. There are many controversies concerning the biological characteristics, prognosis and optimal treatment of these tumors owing to the rarity of incidence. The aims of this study were to elucidate the clinicopathologic characteristics of these tumors and to assist in elucidating the optimal treatment plan for the disease.
MATERIALS AND METHODS
13 cases of primary sarcoma and 10 cases of SMC that had been treated at KCCH between 1984 and 2001 were retrospectively reviewed. Phyllodes tumors were excluded from our study.
RESULTS
Among the 13 cases of primary sarcoma included, stromal sarcoma occurred in 5 cases, osteosarcoma in 3 cases, angiosarcoma in 3 cases and spindle cell sarcoma in 2 cases. The mean age of the patients with primary sarcoma and SMC was 39.7 years and 55.1 years respectively (p=0.002). When survival rates were compared according to histologic types, size of tumor, histologic grade, type of surgery and use of adjuvant therapy, both size of tumor (p=0.0256) and histologic grade (p=0.0197) were shown to be prognostic factors.
CONCLUSION
There were no significantly different features between primary sarcoma and SMC in terms of biologic characteristics or survival rates, with the exception that patients with SMC were older than those with primary sarcoma. Histologic grade and size of tumor were significant prognostic factors of these tumors.

Citations

Citations to this article as recorded by

Primary breast osteosarcoma: A case report and review of the literature
Ramesh Omranipour, Fereshteh Ensani, Maryam Hassanesfahani
Clinical Case Reports.2021;[Epub] CrossRef

4,113 View
39 Download
1 Crossref

Efficacy of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer: Byung Su Kim, Do Youn Oh, Yo Han Joh, Do Yeun Kim, Jee Hyun Kim, Se Hoon Lee, Dae Ho Lee, Tae You Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; Cancer Res Treat. 2001;33(6):469-473. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.469

Abstract PDF

PURPOSE
To evaluate the efficacy and toxicity of combination chemotherapy with low-dose paclitaxel and cisplatin in patients with advanced non-small cell lung cancer.
MATERIALS AND METHODS
Chemotherapy-naive patients with unresectable, pathologically proven non-small cell lung cancer were eligible for inclusion in the study. Patients received paclitaxel (145 mg/m2 iv 3 hour D1) and cisplatin (60 mg/m2 iv D1) every 3 weeks.
RESULTS
Forty-two patients were enrolled between February 2000 and February 2001. The median age was 53.5 years. Patients with adenocarcinoma numbered 29, squamous cell carcinoma 7, large cell carcinoma 3, and undifferentiated carcinoma 3. Seventeen patients had stage IIIB, 19 had stage IV disease and the remaining 6 displayed recurred disease after previous surgical resection. Four patients terminated treatment early because of hypersensitivity (1) and severe emesis (3). Of the 38 evaluable patients, 14 had PR and the response rate was 36.8%. Among partial responders, 6 patients received additional chest radiation. The median duration of response was 47.9 weeks and the median overall survival was 54.0 weeks. Of the total 176 courses, 14 were delayed, 22 required dose reduction, and grade 3~4 neutropenia occurred in 5.6% of courses. Only one episode of neutropenic fever developed and there were no treatment- related mortalities. Other toxicities were generally mild.
CONCLUSION
The combination chemotherapy with low-dose paclitaxel and cisplatin was effective and tolerable in patients with advanced non-small cell lung cancer.

Citations

Citations to this article as recorded by

Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer
Keun-Wook Lee, Jee Hyun Kim, Tak Yun, Eun Kee Song, Im il Na, Hyunchoon Shin, So Yeon Oh, In Sil Choi, Do-Youn Oh, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Jong Seok Lee, Dae Seog Heo, Yung-Jue Bang, Noe Kyeong Kim
Journal of Korean Medical Science.2007; 22(Suppl): S115. CrossRef
Phase II Trial of Low-dose Paclitaxel and Cisplatin in Patients with Advanced Gastric Cancer
Keun-Wook Lee, Seock-Ah Im, Tak Yun, Eun Kee Song, Im il Na, Hyunchoon Shin, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Dong-Wan Kim, Tae-You Kim, Jong Seok Lee, Dae Seog Heo, Yung-Jue Bang, Noe Kyeong Kim
Japanese Journal of Clinical Oncology.2005; 35(12): 720. CrossRef

4,443 View
27 Download
2 Crossref

Clinical Features of Neuroendocrine Lung Cancer: Eun Kyoung Kim, Geun Doo Jang, Cheol Won Suh, Sang We Kim, Sang Do Lee, Woo Seong Kim, Jung Shin Lee, Ho Jung Lee, In Cheol Lee; Cancer Res Treat. 2001;33(6):474-477. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.474

Abstract PDF: PURPOSE
This study was performed to investigate the clinical features of neuroendocrine lung cancer.
MATERIALS AND METHODS
We performed a retrospective review of the histopathology and clinical information of 21 patients diagnosed as having neuroendocrine lung cancer between 1995 and 1999.
RESULTS
Nineteen cases were male and 2 were female. The median age was 64 years (range: 45~80). Pathologic classification were atypical carcinoid (AC) in 2 cases, large cell neuroendocrine carcinoma (LCNEC) in 7 cases, and intermediate cell neuroendocrine carcinoma (ICNC) in 12 cases. Nine patients received tumor resection as first line therapy; adjuvant chemotherapy was given to 3 patients. Concurrent chemoradiotherapy was given to 1 patient. Six patients received palliative chemotherapy. The chemotherapy regimen included etoposide cisplatin in 5 cases and vinorelbine+cisplatin in 1 case. The median survival times were 11, 16 and 59 weeks for AC, LCNEC and ICNC, respectively. The estimated 2-year survival rates were AC 0%, LCNEC 22% and ICNC 31%.
CONCLUSION
Surgery may have a positive effect on survival in patients with early stage cansers. Further investigation is required to improve survival in cases of advanced stage cancer.

3,889 View
24 Download

Reoperation of Recurrent Gastric Cancer: Seung Man Park, Chul Hee Lee, Cho Hyun Park, Wook Kim, Chang Jun Ahn, Geun Woo Lim, Woo Bae Park, Seung Nam Kim, In Chul Kim; Cancer Res Treat. 2001;33(6):478-482. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.478

Abstract PDF

PURPOSE
The aim of this study was to evaluate the outcome of reoperation in recurrent gastric cancers.
MATERIALS AND METHODS
We conducted a retrospective analysis of 86 patients who underwent reoperation for recurrent gastric cancer. We reviewed the time interval between first operation and reoperation, as well as the recurrence pattern, type of reoperation, and survival following reoperation.
RESULTS
the average time to reoperation following curative resection was 27.8+/-25.9 months (median 18.4 months). Fifty-three cases (61.6%) of reoperation were performed within 2 years follwoing the first operation. The most common reason for reoperation was intestinal obstruction followed by gastric remnant recurrence and intra-abdominal mass. Complete resection was possible in 14 cases (16.3%) and a palliative procedure such as partial resection or bypass procedures was performed in 54 cases. In 18 cases (20.9%), simple lapalotomy was done without any aid. The most common site of recurrence was the peritoneum followed by the gastric remnant, distant lymph node and hematogenous liver metastasis. Operative mortality was 10.5%. Excluding the 9 cases of operative mortality, the mean survival time after reoperation was 15.4+/-2.5 months (mean 8.6 months). Survival following complete resection was much longer than palliative procedure and exploration only (37.9+/-8.7 vs 10.9+/-1.5 vs 4.7+/-0.8 months, p=0.000) Conclusion : The complete resection of recurrent gastric cancer can prolong survival. Early detection of localized recurrence is important in order to increase the chance of complete resection.

Citations

Citations to this article as recorded by

Management Strategies for Locoregional Recurrence in Early-Stage Gastric Cancer: Retrospective Analysis and Comprehensive Literature Review
Ahmed Salem, Sameh Hashem, Layth Y. I. Mula-Hussain, Issa Mohammed, Ala’a Nour, Wael Shelpai, Faiez Daoud, Basem Morcos, Yasser Yamin, Imad Jaradat, Jamal Khader, Abdelatief Almousa
Journal of Gastrointestinal Cancer.2012; 43(1): 77. CrossRef
Stereotactic Body Radiotherapy for Isolated Para-aortic Lymph Node Recurrence after Curative Resection in Gastric Cancer
Mi-Sook Kim, Sung Yul Yoo, Chul Koo Cho, Hyung Jun Yoo, Kwang Mo Yang, Jin Kyu Kang, Dong Han Lee, Jong Inn Lee, Ho Youn Bang, Min Suk Kim, Hae Jin Kang
Journal of Korean Medical Science.2009; 24(3): 488. CrossRef
Usefulness of Reoperation after Recurrence of Gastric Cancer
Gui-Ae Jeong, Gyu-Seok Cho, Moon-Su Lee, Yong-Jin Kim, Kil-Ho Kang, Hyung-Soo Kim, Hyung-Chul Kim
Journal of the Korean Surgical Society.2009; 77(2): 96. CrossRef

4,395 View
18 Download
3 Crossref

Clinical Significance of Peripheral Blood CEA mRNA Expression in Gastric Cancer Patients Underwent Curative Resection: Jae Hong Seo, Sun Hee Park, Chang Won Bak, Chul Won Choi, Byoung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Young Jae Mok, Jong Suk Kim, Seon Ae Han, Jung In Yoon; Cancer Res Treat. 2001;33(6):483-488. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.483

Abstract PDF: PURPOSE
Recent advances in molecular technology have made it possible to detect small numbers of circulating tumor cells in the peripheral blood or bone marrow. Carcinoembryonic antigen (CEA) is an oncofetal antigen that is expressed in epithelial tumor cells. CEA mRNA may be a reliable marker for the detection of tumor cells in the peripheral blood of patients with epithelial cancer.
MATERIALS AND METHODS
We analyzed the peripheral blood of 46 patients with gastric cancer who had undergone curative resection. The presence of CEA mRNA was serially monitored using RT-PCR (Preop, Post op 15 day, 2 months (m), 4 m, 6 m, 8 m, 10 m, 12 m). The clinical characteristics, serum CEA level and immunohistochemical staining of tumor tissue were also evaluated. Patients were followed up for 6 to 12 months.
RESULTS
There was no significant relationship seen between CEA mRNA RT-PCR positivity in the peripheral blood and sex, stage, serum CEA level or immunohistochemical staining for CEA antigen, During follow up,eight patients experienced recurrence; were positve for CEA mRNA RT-PCR recurrence was seen in 66.7% (6/9) of the patients who before clinical recurrence as compared to 5.4% (2/37) of patients who were negative (p=0.0002). Serial changes of CEA mRNA RT-PCR correlated with clinical recurrence; 100% in the positively converted group (3/3), 0% in the negatively converted group(0/18), 50% in all positive group (3/6) and 10.5% in all negative group (2/19) experienced recurrence, respectively.
CONCLUSION
RT-PCR analysis of CEA mRNA in the peripheral blood seems to be a promising tool for the early detection of micrometastatic circulating tumor cells in gastric cancer patients and may be useful in determining patients at high risk for recurrence. However, definitive correlation with recurrence certainly requires a longer follow up duration in further studies.

4,808 View
18 Download

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregional Esophageal Cancer: Gyeong Won Lee, Jung Hun Kang, Hun Gu Kim, In Gyu Hwang, Ki Shik Shim, Seok Hyun Kim, Won Sep Lee, Woon Tae Jung, Ok Jae Lee, Jung Hyeun Cho, Joung Soon Jang, Kyu Yong Chae, Jong Seok Lee; Cancer Res Treat. 2001;33(6):489-494. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.489

Abstract PDF

PURPOSE
The object of this study is to evaluate the efficacy and toxicity of induction chemotherapy followed by concomitant chemoradiotherapy in locoregional esophageal cancer.
MATERIALS AND METHODS
Between December 1992 and December 1999, 43 patients with locoregional esophageal cancer were enrolled in this phase II trial. Patients were treated with 2-cycles of induction chemotherapy followed by concomitant chemoradiotherapy. F-P chemotherapy consists of 1,000 mg/m2/Day of 5-FU as continuous infusion on day 1~5 and 80 mg/m2 of cisplatin as an intravenous bolus on day 1 and was repeated every 3~4 weeks. All patients received 60 Gy of external beam radiation concomitantly with F-P chemotherapy; intraluminal brachytherapy was added in 12 patients. A total of 4 cycles of chemotherapy were delivered. No further treatment was planned in patients who achieved complete remission after completion of the treatment.
RESULTS
Among the 43 patients entered, 35 patients completed the protocol. Of the 35 evaluable patients, 12 patients (34%) achieved complete response and 13 patients (37%) achieved partial response. In 26 of 33 patients, dysphagia was improved. At a median follow-up of 22 months, the 2-year and 5-year survival rates were 39% and 19%, respectively. The median survival duration of the complete responder group was 69 months (4~100 months) and the 2-year survival rate of the complete responder group was 82%. Toxicities were tolerable, comprised of mucositis and cytopenia.
CONCLUSION
Induction chemotherapy followed by concurrent chemoradiotherapy in locoregional esophageal cancer is well tolerated and effective.

Citations

Citations to this article as recorded by

A Clinical Scoring Model to Predict the Effect of Induction Chemotherapy With Definitive Concurrent Chemoradiotherapy on Esophageal Squamous Cell Carcinoma Prognosis
Yang Li, Qingwu Du, Xiaoying Wei, Zhoubo Guo, Tongda Lei, Yanqi Li, Dong Han, Xiaoyue Wu, Kunning Zhang, Tian Zhang, Xi Chen, Jie Dong, Baozhong Zhang, Hui Wei, Wencheng Zhang, Qingsong Pang, Ping Wang
Frontiers in Oncology.2021;[Epub] CrossRef
Salvage Esophagectomy for Locoregional Failure After Chemoradiotherapy in Patients With Advanced Esophageal Cancer
Changhoon Yoo, Ji Hyun Park, Dok Hyun Yoon, Seung-Il Park, Hyeong Ryul Kim, Jong Hoon Kim, Hwoon-Yong Jung, Gin Hyug Lee, Kee Don Choi, Ho June Song, Ho-Young Song, Ji Hoon Shin, Kyung-Ja Cho, Yong Hee Kim, Sung-Bae Kim
The Annals of Thoracic Surgery.2012; 94(6): 1862. CrossRef

4,508 View
32 Download
2 Crossref

Mutation of Ha-ras Oncogene in Rat Salivary Gland Tumors Induced by DMBA: Byung Il Yeh, Dong Pyou Han, Joon Hyung Sohn, Joon Ho Yoon, Hye An Lee, Sei Jin Chang, In Deok Kong, Hyun Won Kim, Jong Whan Choi; Cancer Res Treat. 2001;33(6):495-499. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.495

Abstract: PURPOSE
The incidence of salivary gland tumor is approximately 2% among all head and neck tumors, of which malignant cases account for only about 5%. Much research has been performed in order to clarify the mechanism of oncogene activation, however salivary gland tumors remain understudied. We performed this study in order to characterize the ras gene in these tumors.
MATERIALS AND METHODS
We treated white rats with 7, 12-dimethylbenz[a]anthracene (DMBA) and confirmed the occurrence of salivary gland tumors after ten to thirty weeks. Isolated genomic DNAs from tumor tissues were added to NIH 3T3 cells. In order to detect Ha-ras mutations, we performed a two-step PCR-RFLP and 7analyzed the mutated sequences.
RESULTS
We induced salivary gland tumors by DMBA treatment in white rats. Isolated DNAs from the tumor tissues transformed the NIH 3T3 cells. Point mutations were observed in codons 12 and 61 of the Ha-ras oncogene. The total frequency of point mutations was 13.9% in DMBA-induced salivary gland tumors in rats.
CONCLUSION
Our results demonstrate that a variety of cancers ras oncogene mutations were also found in salivary gland tumors. We confirmed that a point mutation of the Ha-ras oncogene in a DMBA-induced salivary gland tumor occurs at a frequency of 13.9%.

3,705 View
15 Download

Evaluation of E1B-mutant Replicating Adenoviruses for Cancer Gene Therapy: Jae Sung Kim, Joo Hang Kim, Heui Ran Lee, Kyeong Cheon Jung, Chae Ok Yun; Cancer Res Treat. 2001;33(6):500-511. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.500

Abstract PDF: PURPOSE
Gene-attenuated replication-competent adenoviruses are emerging as a promising new modality for the treatment of cancer. In an effort to continually improve upon cancer gene therapy, we have modified gene- attenuated replication-competent adenoviruses so as to cause them to replicate efficiently and lyse the infected cancer cells more effectively.
MATERIALS AND METHODS
We modified the E1 region of the adenovirus (Ad) systematically, generating Ad-deltaE1B19, Ad-deltaE1B55, Ad-deltaE1B19/55, and Ad-WT. The cytopathic effects (CPE) and viral replication of these four gene modified adenoviruses were compared, and the morphology and DNA fragmentation of the infected cells was evaluated.
RESULTS
Among the constructed adenoviruses, E1B 19kD-inactivated adenovirus (Ad-deltaE1B19) was the most potent, inducing the largest-sized plaques and markedCPE. Moreover, cells infected with Ad-deltaE1B19 showed complete cell lysis with disintegrated cellular structure whereas cells infected with Ad-WT maintained intact cellular and nuclear membrane with properly structured organelles. TUNEL assay was also used to monitor DNA integrity, and a more profound induction of apoptosis was observed in the Ad-deltaE1B19 infected cells in comparison to wild type adenovirus infected cells.
CONCLUSION
We demonstrate that the inactivation of the E1B19kD gene in a replicating adenovirus leads to increased CPE, rapid viral release, improved cell-to-cell viral spread and increased induction of apoptosis.

4,194 View
30 Download

Proportion of Death Certificate Only Cases and Its Related Factors, Kwangju Cancer Registry (KCR): Su Jin Lee, Min Ho Shin, Sang Young Kim, Kyeong Soo Park, Young Jin Kim, Tai Ju Hwang, Jin Su Choi; Cancer Res Treat. 2001;33(6):512-519. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.512

Abstract PDF: PURPOSE
To ascertain the factors associated with the proportion of death certificate only (DCO) cases contained in the Kwangju Cancer Registry (KCR) that are not as yet in the good range.
MATERIALS AND METHODS
The distribution of DCO cases was analyzed by sex, age, cancer site, histological verification (HV) as well as the physician's death certificate status.
RESULTS
All cases (n=4,243) in Kwangju diagnosed as having cancer between 1997 and 1998 were registered with the KCR. Death certificates (n=2,390) reporting cancer as the causes of death were collected from the National Statistics Office and reviewed with hospital data linkage and a total of 590 cases were registered as DCO. DCOs accounted for 12.2% (male 12.8%, female 11.5%) of all registrations in Kwangju, 1997~1998. The proportion of DCO cases was high in subjects under 15 (male13.5%,female 9.4%) as well as those 75 and over (male 20.3%, female 27.2%). For cancer sites, the proportion of DCO cases was high (over 10%) for liver, bronchus-lung, esophagus and pancreas and low (under 3%) for skin, bladder, uteri cervix and breast. The proportion of DCO cases was inversely associated with HV%. When the death certificate was issued by physician, the possibility of DCO decreased.
CONCLUSION
The proportion of DCO is positively associated with increasing age and negatively associated with HV% and the issuance of a physician's death certificate. These findings suggest that further socio-cultural efforts are required to reduce the DCO proportion.

4,129 View
24 Download

Efficacy of Pre- and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities: Joo Hyuk Sohn, Sun Young Rha, Hei Cheul Jeung, Hyun Joon Shin, Young Suck Goo, Hyun Cheol Chung, Woo Ick Yang, Soo Bong Hahn, Kyu Ho Shin, Jin Sik Min, Byung Soo Kim, Jae Kyung Roh, Woo Ick Jang; Cancer Res Treat. 2001;33(6):520-526. Published online December 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.6.520

Abstract PDF

PURPOSE
We evaluated the treatment efficacy including survival and recurrence, and factors associated with recurrence in osteosarcoma patients treated with preoperative chemotherapy, surgery, and adjuvant chemotherapy.
MATERIALS AND METHODS
Forty nine patients with osteosarcoma were treated with preoperative chemotherapy with intra-arterial cisplatin and adriamycin infusion for 3 cycles, followed by surgery. According to the pathologic response, if tumor was necrotized more than 90%, the same adjuvant chemotherapy was reintroduced for 3 cycles, and if the response was not enough, then the salvage regimen was introduced. Plain chest film and chest CT scan were taken monthly and every 3 months, respectively. When tumor recurred, the metastasectomy was performed whenever possible.
RESULTS
Forty three patients were evaluable with amedian follow up of 53 months. Five-year disease-free and overallsurvival rate was 47.0% and 66.9%, respectively. The recurrence was observed in 22 patients (51.2%) with median time of 12.5 months. Baseline alkaline phosphatase (ALP) was the only significant factor for recurrence (p=0.03) and the patients with the possibility of metastasectomy recurrence showed higher post-relapse survival compared to other treatment modalities (26 momths vs 5~12 months).
CONCLUSION
These results indicates that pre- and postoperative chemotherapy with intra-arterial cisplatin and adriamycin infusion showed comparable treatment efficacy and acceptable toxicities.

Citations

Citations to this article as recorded by

Loading comparison of two structures in the moving tube of a non-invasive prosthesis
Jie Zhang, Ping Ye, Lizheng Zhang, Hongliu Wu, Tianxi Chi, Zhaohua Chang
Technology and Health Care.2021; 29(5): 1001. CrossRef
The multidisciplinary treatment of osteosarcoma of the proximal tibia: a retrospective study
Junqi Huang, Wenzhi Bi, Gang Han, Jinpeng Jia, Meng Xu, Wei Wang
BMC Musculoskeletal Disorders.2018;[Epub] CrossRef
Expression change of ezrin as a prognostic factor in primary osteosarcoma
Yao Fei Wang, Jing Nan Shen, Xian Biao Xie, Jin Wang, Gang Huang
Medical Oncology.2011; 28(S1): 636. CrossRef
Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity
Soojung Hong, Sang Joon Shin, Minkyu Jung, Jaeheon Jeong, Young Joo Lee, Kyoo-Ho Shin, Jae Kyung Roh, Sun Young Rha
Oncology.2011; 80(1-2): 107. CrossRef
Clinical Value of Ezrin Expression in Primary Osteosarcoma
Chan Kim, Eunah Shin, Soojung Hong, Hong Jae Chon, Hye Ryun Kim, Jung Ryun Ahn, Min Hee Hong, Woo Ick Yang, Jae Kyung Roh, Sun Young Rha
Cancer Research and Treatment.2009; 41(3): 138. CrossRef
Carboxypeptidase-G2 Rescue in a Patient with High Dose Methotrexate-induced Nephrotoxicity
Eun Sil Park, Kyung Hee Han, Hyoung Soo Choi, Hee Young Shin, Hyo Seop Ahn
Cancer Research and Treatment.2005; 37(2): 133. CrossRef

4,806 View
36 Download
6 Crossref

First
Prev
Page of 1
Next
Last

Previous issues